Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement

Charles River Laboratories International, Inc.

today announced that it has extended its initial three-year partnership with AstraZeneca

for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZeneca's preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics). James C. Foster, Chairman, President and Chief Executive Officer of Charles River said, "We are extremely pleased that AstraZeneca has chosen to extend its relationship with Charles River. Our combined scientific expertise has been pivotal to enabling AstraZeneca to create a flexible research platform to deliver innovative health solutions. We are proud of the